Patient P-01312
Therapy response
Favorable
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Deteriorating
Nutritional resilience
Favorable
Discontinuation risk
11%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S12
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Inflammatory activity+5
- Nutritional resilience+2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion17.5/100
worsening · +2.3 vs previous 14 d
Toxicity
Blood9.8/100
improving · -9.4 vs previous 14 d
Sleep quality
Wearable37.2/100
stable · +1.2 vs previous 14 d
Energy level
Daily log7.2/10
stable · +0.0 vs previous 14 d
Stress level
Daily log4/10
improving · -0.3 vs previous 14 d
Steps
Wearable5,082
improving · +260 vs previous 14 d
Adherence
Companion90.9 %
stable · -1.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 95 from the failing basin, 11 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More histamineGI -2.7 next day on high-intake days · n 14
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load-2.7supporter · 63%
- Alcohol+1.6no signal · 34%
- Insoluble fibre+1.4no signal · 34%
- Simple carbohydrates-0.8no signal · 18%
- Dietary fat load+0.1no signal · 15%
- Spicy / capsaicin0no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Autonomic recovery ↑20
- WearableShort sleep window
- Inflammatory signalling ↑15
- WearableHRV 36 ms, trending down
DNA
Fictional pharmacogenomic panel
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 4.5 · butyrate capacity 75/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 32 ms
- Sleep
- 6.4 h
- Steps
- 6,223
- Resting HR
- 56 bpm
Daily log: GI score 18, nutritional resilience 66, adherence 91.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01766 | 42% | S05 | AD-05 | no change | 90 |
| P-01804 | 29% | S19 | AD-05 | improved | 61 |
| P-01495 | 54% | S07 | BR-03 | improved | 85 |
| P-01329 | 44% | S08 | BR-03 | improved | 79 |
| P-01677 | 39% | S05 | BR-03 | no change | 86 |
| P-01654 | 56% | S08 | CR-01 | improved | 85 |
| P-01430 | 25% | S05 | CR-01 | improved | 54 |
| P-01479 | 38% | S15 | DT-01 | improved | 84 |
| P-01855 | 33% | S04 | DT-01 | improved | 73 |
| P-01767 | 30% | S14 | DT-01 | no change | 63 |
| P-01724 | 28% | S10 | DT-01 | improved | 63 |
| P-01346 | 26% | S12 | DT-01 | improved | 52 |